{"id":"dapt-strategy","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":{"chemblId":"CHEMBL177969","moleculeType":"Small molecule","molecularWeight":"446.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPT typically combines aspirin with a P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) to provide synergistic antiplatelet effects. This dual approach reduces platelet aggregation through different mechanisms, lowering the risk of stent thrombosis and recurrent ischemic events in patients undergoing percutaneous coronary intervention or with acute coronary syndromes.","oneSentence":"DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:25.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)"},{"name":"Secondary prevention of thrombotic events post-PCI with stent placement"},{"name":"Stable coronary artery disease management"}]},"trialDetails":[{"nctId":"NCT07480629","phase":"","title":"The 10-Year Extended Follow-up of the DACAB Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2026-03-15","conditions":"Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass","enrollment":500},{"nctId":"NCT07257198","phase":"PHASE3","title":"Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-03-03","conditions":"NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial Infarction","enrollment":2570},{"nctId":"NCT07007143","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-07-31","conditions":"Mitral Regurgitation","enrollment":1032},{"nctId":"NCT07391358","phase":"NA","title":"DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid","status":"NOT_YET_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-02-01","conditions":"Acute Coronary Syndrome","enrollment":26},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":"Acute Coronary Syndrome","enrollment":1000},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":"Acute Myocardial Infarction","enrollment":2312},{"nctId":"NCT05732701","phase":"NA","title":"Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-27","conditions":"Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease","enrollment":2788},{"nctId":"NCT04753749","phase":"NA","title":"Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy","status":"COMPLETED","sponsor":"MicroPort CRM","startDate":"2021-03-25","conditions":"Myocardial Infarction, Acute, Coronary Artery Disease","enrollment":2248},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT05631769","phase":"PHASE4","title":"HOST - DAPT Duration According the Bleeding Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-07-24","conditions":"Coronary Artery Disease, Acute Myocardial Infarction, Stable Angina","enrollment":4900},{"nctId":"NCT07068490","phase":"","title":"Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-10-22","conditions":"Coronary Artery Disease","enrollment":100000},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT04418479","phase":"PHASE4","title":"SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3","status":"COMPLETED","sponsor":"Joo-Yong Hahn","startDate":"2020-08-10","conditions":"Coronary Artery Disease","enrollment":5506},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05077683","phase":"PHASE3","title":"Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-10","conditions":"Myocardial Infarction, Acute, Left Ventricular Thrombus","enrollment":560},{"nctId":"NCT03419325","phase":"EARLY_PHASE1","title":"A Genomic Approach for Clopidogrel in Caribbean Hispanics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Puerto Rico","startDate":"2020-09-01","conditions":"Cardiovascular Disease (CVD), Stroke, Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT06000943","phase":"","title":"Ischemic And Bleeding Risk Assessment After TAVR","status":"UNKNOWN","sponsor":"Niguarda Hospital","startDate":"2023-08-01","conditions":"Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement","enrollment":2500},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT05671276","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Occlusion, Silent Cerebral Embolism","enrollment":150},{"nctId":"NCT05554822","phase":"PHASE3","title":"Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study","status":"UNKNOWN","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2021-06-14","conditions":"Left Atrial Appendage Occlusion, Antiplatelet Therapy","enrollment":574},{"nctId":"NCT01813435","phase":"PHASE3","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2013-07-01","conditions":"Coronary Artery Disease (CAD)","enrollment":15991},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT02217501","phase":"PHASE3","title":"Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-11","conditions":"Peripheral Arterial Disease","enrollment":159},{"nctId":"NCT04502017","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2020-08-05","conditions":"Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion","enrollment":360},{"nctId":"NCT03848572","phase":"NA","title":"Repetitive Assessement of PRECISE-DAPT Score","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2017-06-01","conditions":"Cardiovascular Diseases, Interventional Cardiology","enrollment":500},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT02362659","phase":"","title":"Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-04","conditions":"Non-valvular Atrial Fibrillation","enrollment":514},{"nctId":"NCT02494284","phase":"PHASE4","title":"Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation","status":"TERMINATED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-12-22","conditions":"Coronary Artery Disease","enrollment":364}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DAPT strategy","genericName":"DAPT strategy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of thrombotic events post-PCI with stent placement, Stable coronary artery disease management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}